Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/AstraZeneca faces securities fraud probe after trial failure causes stock drop

AZN

$169.64

-$1.70 -0.99%

AstraZeneca faces securities fraud probe after trial failure causes stock drop

Market News

30 Jul 2026

PRNewsWire

View Source

Bearish

AstraZeneca disclosed that its Phase-3 trial for Wainua, a treatment for amyloid cardiomyopathy, failed to meet its primary endpoint, causing its stock to drop 5.7% on July 9, 2026. Following this, Pomerantz LLP announced an investigation into whether AstraZeneca and some of its executives engaged in securities fraud or unlawful business practices. Investors affected by the stock decline are being advised to consider joining a class action lawsuit. This legal action could impact AstraZeneca's reputation and financial standing as the case develops.

More News (AZN)

AstraZeneca and Bristol Myers Squibb consider $400B merger to create pharma giant

UK pharmaceutical company AstraZeneca is in talks to merge with US rival Bristol Myers Squibb, potentially forming a combined entity valued at around $400 billion. The merger would be one of the largest in history, combining AstraZeneca's global reac...

Company Fundamentals

Bullish

5 hours ago